Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study


Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and the highest therapeutic index among spicamycin derivatives. KRN5500 is currently under clinical development in Japan and the United States. The objective of this study was to develop a population pharmacokinetic model that describes the… (More)
DOI: 10.1007/s002800000257


  • Presentations referencing similar topics